Clinical Trial Update: TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TRC105 with standard-dose bevacizumab in two patients with metastatic and refractory choriocarcinoma has completed; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choriocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• TRC105 (carotuximab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Choriocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-06-11